Pulmonary artery-targeted low-dose metformin-loaded nanocapsules safely improve pulmonary arterial hypertension in rats
Frontiers in Pharmacology · 30.04.2025 · 16
DOI: 10.3389/fphar.2025.1577570 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.04.2025. Verfasst von Ayako Chida-Nagai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Hokkaido University Hospital, Sapporo, Japan. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Pulmonary arterial hypertension (PAH) remains a challenge to tackle despite various available medications. Metformin, although promising, has major adverse effects; the use of an appropriate drug delivery method may improve its efficacy and safety. The aim of this study was to develop a novel treatment for PAH using metformin. We developed a novel approach of using low-dose metformin encapsulated in pulmonary artery-targeted nanocapsules to alleviate PAH while avoiding adverse effects.
Methods
Metformin-loaded lung-targeted nanocapsules (MET nanocapsules) were created using a specific lipid composition, including cationic lipids. Their uptake and effects on cell viability were assessed in human pulmonary arterial smooth muscle cells (hPASMCs) from healthy individuals and patients with PAH. Their therapeutic effects were assessed in a PAH rat model. The safety of MET nanocapsules was confirmed using rat serum biochemical tests.
Results
We successfully prepared MET nanocapsules and demonstrated their effectiveness in inhibiting PASMC proliferation. In PAH model rats, MET nanocapsule treatment led to improved hemodynamics, right ventricular hypertrophy, and pulmonary arterial medial thickening. The nanocapsules effectively accumulated in the lungs of PAH model rats.
Conclusion
Intravenous administration of MET nanocapsules is a safe and innovative therapeutic approach for PAH. This method could improve PAH treatment outcomes while minimizing adverse effects, with potential applications in other types of pulmonary hypertension.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Hokkaido University Hospital, Sapporo, Japan.
- Department of Pediatric Cardiology and Adult Congenital Cardiology, Tokyo Women's Medical University, Tokyo, Japan.
- Division of Cardiovascular Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
- Department of Cardiology and Clinical Examination, Oita University, Yufu, Japan.
- Advanced Trauma, Emergency and Critical Care Center, Oita University Hospital, Yufu, Japan.
- Department of Thoracic Surgery, Hokkaido University Hospital, Sapporo, Japan.
Zitieren
APA
Chida-Nagai, A., Masaki, N., Sato, H., Kato, T., Takakuwa, E., Matsuno, Y., Manabe, A., & Takeda, A. (2025). Pulmonary artery-targeted low-dose metformin-loaded nanocapsules safely improve pulmonary arterial hypertension in rats. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1577570
Vancouver
Chida-Nagai A, Masaki N, Sato H, Kato T, Takakuwa E, Matsuno Y, et al. Pulmonary artery-targeted low-dose metformin-loaded nanocapsules safely improve pulmonary arterial hypertension in rats. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1577570
BibTeX
@article{ChidaNagai2025,
author = {Chida-Nagai, Ayako and Masaki, Naoki and Sato, Hiroki and Kato, Tatsuya and Takakuwa, Emi and Matsuno, Yoshihiro and Manabe, Atsushi and Takeda, Atsuhito},
title = {Pulmonary artery-targeted low-dose metformin-loaded nanocapsules safely improve pulmonary arterial hypertension in rats},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1577570}
}
EUVIMED